Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07128355) titled 'Botensilimab, Balstilimab, and SBRT in Colorectal Cancer' on Aug. 13.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Massachusetts General Hospital
Condition:
Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis
Intervention:
Radiation: Stereotactic Body Radiation Therapy (SBRT)
Drug: Botensilimab
Recruitment Status: Not recruiting
Phase: Early Phase 1
Date of First Enrollment: January 2026
Target Sample Size: 15
Countries of Recruitment:
United States
To know more, vis...